Compare Cloudflare Inc (NET) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cloudflare Inc vs Recursion Pharmaceuticals Inc — how do they compare? Cloudflare Inc trades at $343.23 (market cap $122.12B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.31B). The key difference: Cloudflare Inc is far larger — about 52.9× Recursion Pharmaceuticals Inc's market cap, and Cloudflare Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cloudflare Inc for 61 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| NET | RXRX | |
|---|---|---|
Market Cap | $122.12B | $2.31B |
Volume | 2,321,930 | 40,478,768 |
Sector | Technology | Health |
52-Week High | $359.60 | $6.79 |
52-Week Low | $160.16 | $2.84 |
Typical Hold Time | 61 Days | 22 Days |
Enterprise Value | $121.49B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cloudflare (NET) trades at $341.70, down 3.75% on the day, with a bullish technical signal from moving averages and neutral oscillators. Revenue growth is strong, reaching $2.17 billion in 2025, but the company remains unprofitable with a net income margin of -8.21%. Recent news highlights product launches like Cloudflare Basin and partnerships, such as with Deutsche Telekom, driving positive sentiment. The stock is near its 52-week high, reflecting investor optimism around its AI and security offerings.
Outlook is mixed: robust revenue growth and analyst bullishness (70.7% buy ratings) support upside, but high valuations (P/S of 48.03) and persistent losses pose risks. Investors should weigh growth potential against profitability challenges and market volatility.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cloudflare Inc
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
